Intrinsiqs

Is Nektar Therapeutics overvalued?

Nektar Therapeutics (NKTR) — key valuation metrics and fundamentals.

No verdict
Price
$60.40
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.73B
Dividend yield
0.0%
Return on equity
-38.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares NKTR's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.